Azmi Nasser
Supernus Pharmaceuticals, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Azmi Nasser as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:44 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03474770 · BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresSupernus Pharmaceuticals, Inc. · active not recruiting · Focal Impaired Awareness Seizures · study chair
- Ph3NCT02618408 · Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)Supernus Pharmaceuticals, Inc. · completed · Attention Deficit Hyperactivity Disorder (ADHD) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:44 UTC. The ranking covers the 200 most relevant of 38 PubMed records, and a shared surname and initials can bring in a namesake. All 38 on PubMed
- 64 citationsRCR 4.2
- Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.J Clin Psychopharmacol · 201658 citationsRCR 3.1
- A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.J Atten Disord · 202049 citationsRCR 3.9
- Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial.Mol Psychiatry · 202347 citationsRCR 6.2
- Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.J Clin Psychopharmacol · 201645 citationsRCR 2.4
- Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.Clin Ther · 202142 citationsRCR 4.1
- 40 citationsRCR 5.0
- 38 citationsRCR 2.0
- A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.J Clin Psychopharmacol · 202138 citationsRCR 2.9
- 37 citationsRCR 1.7